CoChat

An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis

Open access
Balogh, Dora Bianka, Wagner, Laszlo Jozsef, Fekete, Andrea · 2023 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 152 of the 155 references it cites were found in a registry or an index.

Abstract

Metabolic diseases, particularly diabetes mellitus (DM), are significant global public health concerns. Despite the widespread use of standard-of-care therapies, cardiovascular disease (CVD) remains the leading cause of death among diabetic patients. Early and evidence-based interventions to reduce CVD are urgently needed. Large clinical trials have recently shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) ameliorate adverse cardiorenal outcomes in patients with type 2 DM. These quite unexpected positive results represent a paradigm shift in type 2 DM management, from the sole importance of glycemic control to the simultaneous improvement of cardiovascular outcomes. Moreover, SGLT2i is also found to be cardio- and nephroprotective in non-diabetic patients. Several mechanisms, which may be potentially independent or at least separate from the reduction in blood glucose levels, have already been identified behind the beneficial effect of these drugs. However, there is still much to be understood regarding the exact pathomechanisms. This review provides an overview of the current literature and sheds light on the modes of action of novel antidiabetic drugs, focusing on inflammation, oxidative stress, and fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms24097789

Cites

152 of 152 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The protective effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptors agonists (GLP-1RA), and dipeptidyl-peptidase-4 inhibitors (DPP-4i) in patients with type 2 diabetes mellitus (T2DM). ACC: American College of Cardiology, ADA: American Diabetes Association, AHA: American Heart Association, CKD: chronic kidney disease, CVD: cardiovascular disease, EASD: European Association for the Study of Diabetes, ESC: European Society of Cardiology, ISN: International Society of Nephrology, KDIGO: Kidney Disease: Improving Global Outcomes.
Figure 1 The protective effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptors agonists (GLP-1RA), and dipeptidyl-peptidase-4 inhibitors (DPP-4i) in patients with type 2 diabetes mellitus (T2DM). ACC: American College of Cardiology, ADA: American Diabetes Association, AHA: American Heart Association, CKD: chronic kidney disease, CVD: cardiovascular disease, EASD: European Association for the Study of Diabetes, ESC: European Society of Cardiology, ISN: International Society of Nephrology, KDIGO: Kidney Disease: Improving Global Outcomes.CC BY · PubMed Central
Figure 2 The effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptors agonists (GLP-1RA), and dipeptidyl-peptidase-4 inhibitors (DPP-4i) on inflammation, oxidative stress, and fibrosis. AMPK: adenosine monophosphate-activated protein kinase, ECM: extracellular matrix, hs-CRP: high-sensitivity C-reactive protein, IL-1β: interleukin-1 beta, IL-6: interleukin-6, LV: left ventricle, NF-κB: nuclear factor-κB, NLRP3: Nod-like receptor (NLR) family pyrin domain-containing 3, NOX2: NADPH oxidase 2, NOX4: NADPH oxidase 4, Nrf2: nuclear factor erythroid 2-related factor 2, ROS: reactive oxygen species, TGF-β: transforming growth factor β, TNF-α: tumor necrosis factor-alpha.
Figure 2 The effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptors agonists (GLP-1RA), and dipeptidyl-peptidase-4 inhibitors (DPP-4i) on inflammation, oxidative stress, and fibrosis. AMPK: adenosine monophosphate-activated protein kinase, ECM: extracellular matrix, hs-CRP: high-sensitivity C-reactive protein, IL-1β: interleukin-1 beta, IL-6: interleukin-6, LV: left ventricle, NF-κB: nuclear factor-κB, NLRP3: Nod-like receptor (NLR) family pyrin domain-containing 3, NOX2: NADPH oxidase 2, NOX4: NADPH oxidase 4, Nrf2: nuclear factor erythroid 2-related factor 2, ROS: reactive oxygen species, TGF-β: transforming growth factor β, TNF-α: tumor necrosis factor-alpha.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Cited by

See all 44

Metadata

Authors
Balogh, D. B., Wagner, L. J., & Fekete, A.
Affiliations
Semmelweis University (HU)
Corresponding author
Fekete, Andrea
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-04-24
Volume
24
Issue
9
Pages
7789
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4366989020
Cited by
38
References
155
Citations by year
2026: 12 · 2025: 15 · 2024: 8 · 2023: 3
FWCI
1.37
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • New National Excellence Program of The Ministry for Culture and Innovation (UNKP-22-4-II-SE-2, TKP2021-EGA-24)
  • Ministry of Innovation and Technology of Hungary (UNKP-22-4-II-SE-2, TKP2021-EGA-24)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
cardioprotection, type 2 diabetes, cardiovascular disease, SGLT2 inhibitors, GLP-1 receptor agonists, inflammation, oxidative stress, myocardial fibrosis, cardiorenal outcomes, drug mechanisms of action
MeSH terms
Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fibrosis, Humans, Hypoglycemic Agents, Inflammation, Oxidative Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.